Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax RateWages, Salaries and Other
Others
Ratios

Rhythm Pharmaceuticals (RYTM) Tax Provisions (2021 - 2025)

Rhythm Pharmaceuticals has reported Tax Provisions over the past 4 years, most recently at -$3000.0 for Q4 2025.

  • Quarterly Tax Provisions rose 94.44% to -$3000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $525000.0 through Dec 2025, up 37.8% year-over-year, with the annual reading at $497000.0 for FY2025, 43.64% up from the prior year.
  • Tax Provisions was -$3000.0 for Q4 2025 at Rhythm Pharmaceuticals, down from $111000.0 in the prior quarter.
  • Over five years, Tax Provisions peaked at $22.0 million in Q1 2021 and troughed at -$9.0 million in Q3 2021.
  • The 4-year median for Tax Provisions is $111000.0 (2025), against an average of $727615.4.
  • Year-over-year, Tax Provisions crashed 193.48% in 2024 and then soared 132.27% in 2025.
  • A 4-year view of Tax Provisions shows it stood at -$9.0 million in 2021, then soared by 102.18% to $196000.0 in 2023, then plummeted by 127.55% to -$54000.0 in 2024, then surged by 94.44% to -$3000.0 in 2025.
  • Per Business Quant, the three most recent readings for RYTM's Tax Provisions are -$3000.0 (Q4 2025), $111000.0 (Q3 2025), and $337000.0 (Q2 2025).